Promoting healthy aging and maintaining an active lifestyle has become a prominent trend. People are increasingly interested in preserving their muscle mass and strength as they age. This cultural shift fosters demand for treatments that can help prevent or manage sarcopenia.
People are living longer lives with advances in healthcare and medicine. However, as individuals age, they are more likely to develop sarcopenia. This longer life expectancy contributes to the overall prevalence of the condition. Chronic illnesses can lead to muscle loss and contribute to the development of sarcopenia. The increasing incidence of these conditions has a direct impact on the rising prevalence of sarcopenia.
The demand for effective interventions to prevent or manage sarcopenia is expected to increase, fostering research, development, and innovation in the field of sarcopenia treatment as the world's population ages, which is expected to drive market growth.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/europe-sarcopenia-treatment-market
Data Bridge Market Research analyzes the Europe Sarcopenia Treatment Market is expected to reach USD 1,033,968.39 thousand by 2030 from USD 725,593.95 thousand in 2022, growing with a substantial CAGR of 4.6% in the forecast period of 2023 to 2030.
Key Findings of the Study
Growing Awareness of Sarcopenia and its Detrimental Effects on Health
The growing awareness of sarcopenia and its detrimental effects on health is a significant development in the field of healthcare and aging. There has been a significant increase in research and publications related to sarcopenia. Scientific studies, medical journals, and publications have provided healthcare professionals with valuable information about the condition's prevalence, diagnosis, and consequences. Medical schools and training programs have incorporated sarcopenia into their curricula. This ensures that healthcare professionals, including doctors, nurses, and physical therapists, receive education about sarcopenia, its risk factors, and management strategies.
Various advocacy groups and organizations have been actively promoting awareness about sarcopenia. These groups often collaborate with healthcare professionals to educate the public about the conditions risks and the importance of early diagnosis and intervention. Sarcopenia has received increased coverage in mainstream media, including articles, news reports, and documentaries. This exposure has helped raise awareness among the general public.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015- 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, home healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest of Europe
|
|
Market Players Covered
|
Abbott., (U.S.), Nestlé Health Science (A subsidary of Nestlé S.A.) (Switzerland), Novartis AG (Switzerland), Sanofi (France), Haleon Group of Companies.(England), BASF SE (Germany), DSM (Netherlands), Fermenta Biotech Limited (India), AstaReal Co., Ltd.(Japan), Metagenics (U.S.), Wellona Pharma (India), The Vitamin Company India (India), Healing Pharma India Pvt. Ltd.(India), OPKO Health, Inc.(U.S.), NMD PHARMA A/S (Denmark), Regeneron Pharmaceuticals Inc.(U.S.), Biophytis (France), ARMGO Pharma, Inc.(U.S.), Rejuvenate Biomed NV.(Belgium) and among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Europe sarcopenia treatment market is segmented into seven notable segments such as treatment type, type, stages, route of administration, gender, end user, and distribution channel.
- On the basis of treatment type, the Europe sarcopenia treatment market is segmented into vitamin/dietary supplements, medications, and others.
In 2023, the vitamin/dietary supplements segment is expected to dominate the Europe sarcopenia treatment market
In 2023, the vitamin/dietary supplements segment is expected to dominate the market with a market share of 48.18% due to its increasing demand among the population.
- On the basis of type, the Europe sarcopenia treatment market is segmented into primary sarcopenia, and secondary sarcopenia.
In 2023, the primary sarcopenia segment is expected to dominate the Europe sarcopenia treatment market
In 2023, the primary sarcopenia segment is expected to dominate the market with a market share of 59.17% due to its rising prevalence among population.
- On the basis of stages, the Europe sarcopenia treatment market is segmented into pre-sarcopenia, sarcopenia, and severe sarcopenia. In 2023, the pre-sarcopenia segment is expected to dominate the market with a market share of 42.55%.
- On the basis of route of administration, the Europe sarcopenia treatment market is segmented into oral, injectables, and others. In 2023, the oral segment is expected to dominate the market with a market share of 56.66%.
- On the basis of gender, the Europe sarcopenia treatment market is segmented into male, and female. In 2023, the male segment is expected to dominate the market with a market share of 61.98%.
- On the basis of end user, the Europe sarcopenia treatment market is segmented into hospitals, speciality clinics, home healthcare, and others. In 2023, the hospitals segment is expected to dominate the market with a market share of 53.65%.
- On the basis of distribution channel, the Europe sarcopenia treatment market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the market with a market share of 68.36%.
Major Players
Data Bridge Market Research analyzes Abbott., (U.S.), Nestlé Health Science (A subsidary of Nestlé S.A.) (Switzerland), Novartis AG (Switzerland), Sanofi (France), and Haleon Group of Companies.(England) as the market players in Europe sarcopenia treatment market.
Market Developments
- In August 2023, Haleon, a global leader in consumer health, and Direct Relief, announced that a humanitarian aid organization, have agreed to a multi-year commitment to expand access to everyday health for underserved communities while boosting emergency response and preparedness efforts around the world. This will increase the company brand image.
- In June 2023, Sanofi announced that its consumer healthcare business unit had launched a new open innovation portal, allowing the wider supply chain community to submit their creative, disruptive, and game-changing solutions to meet the challenges of an ever-evolving consumer healthcare landscape. This helps the organisation in developing more revenue.
- In February 2023, Nestlé Health Science announced that they entered into a research collaboration with EraCal Therapeutics, to identify novel nutraceuticals relevant to controlling food intake. This will increase the company product portfolio and overall revenue.
- In November 2022, Abbott announced that it has been awarded by the Consumer Technology Association (CTA) with three CES 2023 innovation awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
- In July 2022, AstaReal Co., Ltd. announced that AstaReal Astaxanthin was awarded cognitive function ingredient of the year 2022. This helped the organization in developing brand image.
Regional Analysis
Geographically, the countries covered in the Europe Sarcopenia Treatment Market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Denmark, Norway, Sweden, Poland, Finland, and Rest of Europe.
As per Data Bridge Market Research analysis:
Germany is the dominating and fastest-growing country in Europe sarcopenia treatment market
Germany is expected to dominate the Europe sarcopenia treatment market owing to the higher level of investments by various manufacturers and increasing demand for pharmaceutical products manufacturing in the country.
For more detailed information about the Europe sarcopenia treatment market report, click here – https://www.databridgemarketresearch.com/jp/reports/europe-sarcopenia-treatment-market
